Page last updated: 2024-12-04

s-tetradecanoyl-coenzyme a

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

myristoyl-CoA : A long-chain fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of myristic acid. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID11966124
CHEBI ID15532
SCHEMBL ID187713
MeSH IDM0120200

Synonyms (21)

Synonym
s-tetradecanoyl-coenzyme a
3'-phosphoadenosine 5'-(3-{(3r)-3-hydroxy-2,2-dimethyl-4-oxo-4-[(3-oxo-3-{[2-(tetradecanoylsulfanyl)ethyl]amino}propyl)amino]butyl} dihydrogen diphosphate)
n-c14:0-coenzyme a
CHEBI:15532
n-c14:0-coa
MYA ,
myristoyl-coa
tetradecanoyl-coa ,
C02593
DB02180
n-myristoyl coenzyme a
ync ,
SCHEMBL187713
myristoylcoenzyme a
coenzyme a, s-myristate
myristyl-coa
LMFA07050352
s-{(3s,5r,9r)-1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3lambda~5~,5lambda~5~-diphosphaheptadecan-17-yl} tetradecanethioate (no
myristoylcoenzymea
CS-0107702
HY-126833

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"The question of polycyclic aromatic hydrocarbon (PAH) bioavailability and its relationship to specific PAH sources with different PAH binding characteristics is an important one, because bioavailability drives PAH accumulation in biota and ultimately the biochemical responses to the PAH contaminants."( Biota: sediment partitioning of aluminium smelter related PAHs and pulp mill related diterpenes by intertidal clams at Kitimat, British Columbia.
Cretney, WJ; Dangerfield, N; Fowler, BR; Lachmuth, CL; Ross, PS; White, L; Yunker, MB, 2011
)
0.37

Dosage Studied

ExcerptRelevanceReference
" FASN expression is up-regulated in cancer, and its activity levels are controlled by gene dosage and transcriptional and post-translational mechanisms."( Crystal Structure and Substrate Specificity of Human Thioesterase 2: INSIGHTS INTO THE MOLECULAR BASIS FOR THE MODULATION OF FATTY ACID SYNTHASE.
Clodfelter, JE; Fulp, BE; Furdui, CM; Johnson, LC; Kridel, SJ; Lowther, WT; Pemble, CW; Ritchie, MK, 2016
)
0.43
"56 ng/g), despite equal dosing concentrations, indicating higher tissue accumulation."( The silence of the clams: Forestry registered pesticides as multiple stressors on soft-shell clams.
Granek, EF; Hladik, ML; Moran, PW; Scully-Engelmeyer, K; Thompson, AW; Tissot, AG, 2022
)
0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
Escherichia coli metaboliteAny bacterial metabolite produced during a metabolic reaction in Escherichia coli.
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
long-chain fatty acyl-CoAA fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of any long-chain (C13 to C22) fatty acid.
11,12-saturated fatty acyl-CoAAny fatty acyl-CoA in which the 11-12 bond of the fatty acyl group is saturated.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (26)

PathwayProteinsCompounds
Metabolism14961108
Metabolism of lipids500463
Fatty acid metabolism113203
Mitochondrial Fatty Acid Beta-Oxidation2260
mitochondrial fatty acid beta-oxidation of saturated fatty acids942
Beta oxidation of palmitoyl-CoA to myristoyl-CoA313
Beta oxidation of myristoyl-CoA to lauroyl-CoA313
Metabolism of nitric oxide: NOS3 activation and regulation1426
eNOS activation and regulation1326
eNOS activation1026
Visual phototransduction6241
The phototransduction cascade2621
Inactivation, recovery and regulation of the phototransduction cascade2518
Disease1278231
Infectious disease89579
HIV Infection20112
HIV Life Cycle13010
Late Phase of HIV Life Cycle1199
Assembly Of The HIV Virion132
Synthesis And Processing Of GAG, GAGPOL Polyproteins42
Membrane binding and targetting of GAG proteins42
Sensory Perception21568
Mitochondrial beta-oxidation064
Viral Infection Pathways72739
Fatty acid beta-oxidation025
Metabolism overview078

Research

Studies (185)

TimeframeStudies, This Drug (%)All Drugs %
pre-199021 (11.35)18.7374
1990's33 (17.84)18.2507
2000's62 (33.51)29.6817
2010's55 (29.73)24.3611
2020's14 (7.57)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews9 (4.81%)6.00%
Case Studies1 (0.53%)4.05%
Observational0 (0.00%)0.25%
Other177 (94.65%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]